Mometasone furoate/formoterol in the treatment of persistent asthma

Abstract

Mometasone furoate and formoterol fumarate dihydrate (MF/F) administered via metered-dose inhaler with a dose counter is a new fixed-dose combination of an inhaled corticosteroid and a long-acting β2-agonist indicated for daily maintenance therapy in patients aged ≥12 years with persistent asthma. Randomized, controlled trials have suggested that MF/F reduces asthma deteriorations while improving lung function and other measures of asthma control, including quality-of-life. Clinical safety studies lasting up to 1 year have found that MF/F has a low incidence of local and systemic side effects.

Keywords::

• anti-inflammatory
• asthma
• asthma deterioration
• β-agonist
• bronchodilator
• control
• corticosteroid
• exacerbation
• inhaler
• quality of life

Financial & competing interests disclosure

WE Berger is an employee of Allergy & Asthma Associates of Southern California, Mission Viejo, CA, USA. He has received grant/research support from and/or served as a consultant, advisory board member and/or speaker for Alcon, AstraZeneca, GlaxoSmithKline, Meda, Merck & Co., Novartis, Sepracor and Teva. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Medical writing and editorial assistance for preparation of this review was provided by Ken Kauffman of Complete Publication Solutions, LLC, Horsham, PA, USA. This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Whitehouse Station, NJ, USA.